Drug Price Trends for BUDESONIDE ER

Average Pharmacy Cost for BUDESONIDE ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
BUDESONIDE ER 9 MG TABLET	00591-2510-30	16.03118	EACH	2025-05-21
BUDESONIDE ER 9 MG TABLET	68682-0309-30	16.03118	EACH	2025-05-21
BUDESONIDE ER 9 MG TABLET	00378-4500-93	16.03118	EACH	2025-05-21
BUDESONIDE ER 9 MG TABLET	68682-0309-30	17.96850	EACH	2025-04-23
BUDESONIDE ER 9 MG TABLET	00591-2510-30	17.96850	EACH	2025-04-23

Budesonide Extended-Release (ER) Market Analysis and Price Projections

Introduction to Budesonide ER

Budesonide is a glucocorticosteroid used in various formulations, including extended-release (ER) tablets, primarily for the treatment of gastrointestinal and respiratory conditions. The ER formulation is specifically indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis, as well as for the treatment of primary biliary cholangitis (PBC)[2][3].

Market Overview

Global Market Size and Growth

The market for budesonide ER is part of the broader glucocorticosteroid market, which is experiencing significant growth driven by increasing prevalence of chronic diseases such as ulcerative colitis and PBC.

• The global budesonide market, including ER formulations, is expected to grow substantially over the forecast period. For instance, the budesonide market for PBC is projected to expand due to extensive research and incremental healthcare spending worldwide[1].

Regional Market Analysis

United States

• In the U.S., the launch of generic versions of budesonide ER tablets has been a significant factor in market growth. For example, Teva Pharmaceutical Industries Ltd. launched a generic version of Uceris® (budesonide) extended-release tablets in 2018, which has contributed to the market's expansion. Uceris® had annual sales of approximately $196 million in the U.S. as of May 2018[2].

Europe

• The European market, including countries such as Germany, France, Italy, Spain, and the UK, is also seeing growth. The market size of budesonide for PBC in these countries is forecasted to increase due to the rising incidence of PBC and the availability of generic versions[1].

Japan and China

• In Japan and China, the market is expected to grow due to increasing healthcare spending and the introduction of new therapies. The detailed country-wise market analysis highlights the potential for significant growth in these regions[1].

Price Projections and Market Dynamics

Impact of Generic Versions

• The introduction of generic versions of budesonide ER tablets has significantly impacted the market by making the drug more affordable and accessible. Generic versions are expected to drive market growth, especially in low- and middle-income economies[2][4].

Competitive Landscape

• The competitive landscape includes several key players such as Teva Pharmaceutical Industries Ltd., Pfizer Inc., Cipla Ltd., and others. These companies are continuously working on developing new therapies and generic versions, which is expected to increase market competition and drive prices down[2][3].

Regulatory Milestones

• Regulatory milestones and developmental activities play a crucial role in shaping the market. Detailed descriptions of regulatory milestones and other developmental activities are essential for understanding the current and future market scenario[1].

Market Size and Forecast

Budesonide Market Size for PBC

• The market size of budesonide for PBC in the seven major markets (7MM) and China is forecasted to grow significantly from 2019 to 2032. The report provides detailed forecasts, including market size in USD million for each country and the overall 7MM and China[1].

Budesonide ER Market Size for Ulcerative Colitis

• For ulcerative colitis, the market size is also expected to grow, driven by the increasing prevalence of the disease and the launch of generic versions. The annual sales of Uceris® and other budesonide ER formulations indicate a substantial market size[2].

SWOT Analysis and Analyst Views

Strengths

• Budesonide ER has a well-established mechanism of action and is effective in inducing remission in patients with ulcerative colitis and PBC.
• The availability of generic versions has increased accessibility and affordability[1][2].

Weaknesses

• Systemic effects such as hypercorticism and adrenal suppression can occur with chronic use of glucocorticosteroids.
• Anaphylactic reactions have been reported with other budesonide formulations[2].

Opportunities

• Emerging therapies and novel approaches to treat PBC and ulcerative colitis present opportunities for market expansion.
• Increasing healthcare spending and the growing prevalence of chronic diseases are driving factors for market growth[1][3].

Threats

• The launch of late-stage emerging therapies for PBC and ulcerative colitis could pose a significant threat to budesonide's market dominance.
• Competition from other generic versions and branded therapies is a continuous challenge[1][3].

Impact of COVID-19

The COVID-19 pandemic has had a mixed impact on the budesonide ER market. On one hand, the pandemic has increased the burden on healthcare systems, but on the other hand, it has highlighted the importance of corticosteroids like budesonide in managing COVID-19 symptoms.

• A study published by the University of Oxford found that early treatment with inhaled budesonide shortened recovery time in non-hospitalized patients with COVID-19, which has driven the growth of the budesonide inhaler market and indirectly supported the ER market[4].

Key Takeaways

• The budesonide ER market is expected to grow significantly driven by the increasing prevalence of chronic diseases and the availability of generic versions.
• Regulatory milestones and developmental activities are crucial for understanding the market's future scenario.
• The competitive landscape is dynamic, with several key players working on new therapies and generic versions.
• The impact of COVID-19 has highlighted the importance of corticosteroids like budesonide in managing various health conditions.

FAQs

What is budesonide ER used for?

Budesonide ER is primarily used for the induction of remission in patients with active, mild to moderate ulcerative colitis and for the treatment of primary biliary cholangitis (PBC)[2].

How does the introduction of generic versions affect the market?

The introduction of generic versions of budesonide ER tablets makes the drug more affordable and accessible, driving market growth, especially in low- and middle-income economies[2][4].

What are the potential side effects of budesonide ER?

Systemic effects such as hypercorticism and adrenal suppression can occur with chronic use of glucocorticosteroids. Anaphylactic reactions have also been reported with other budesonide formulations[2].

How has COVID-19 impacted the budesonide ER market?

The COVID-19 pandemic has highlighted the importance of corticosteroids like budesonide in managing COVID-19 symptoms, indirectly supporting the growth of the budesonide ER market[4].

What is the forecasted market size for budesonide ER?

The market size of budesonide for PBC in the 7MM and China is forecasted to grow significantly from 2019 to 2032, with detailed forecasts provided in USD million for each country and the overall 7MM and China[1].

Who are the key players in the budesonide ER market?

Key players include Teva Pharmaceutical Industries Ltd., Pfizer Inc., Cipla Ltd., and others, who are continuously working on developing new therapies and generic versions[2][3].

Last updated: 2025-01-02